Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials.
作者信息
Ballow Mark, Wasserman Richard L, Jolles Stephen, Chapel Helen, Berger Mel, Misbah Siraj A
机构信息
Department of Pediatrics, Division of Allergy & Immunology, The Johns Hopkins All Children's Hospital, Children's Research Institute, University of South Florida, 140 7th Ave South, St Petersburg, FL, 33701, USA.
Medical City Children's Hospital, Dallas, TX, USA.
出版信息
J Clin Immunol. 2017 Aug;37(6):517-518. doi: 10.1007/s10875-017-0410-x. Epub 2017 Jul 10.
Abstract
摘要
相似文献
1
Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials.临床试验中皮下注射免疫球蛋白（SCIG）局部不良反应的评估。
J Clin Immunol. 2017 Aug;37(6):517-518. doi: 10.1007/s10875-017-0410-x. Epub 2017 Jul 10.
2
Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".对致编辑的信的回复，信的主题为“在临床试验中评估皮下注射免疫球蛋白（SCIG）的局部不良反应”
J Clin Immunol. 2017 Nov;37(8):739-740. doi: 10.1007/s10875-017-0438-y. Epub 2017 Sep 5.
3
Immunoglobulin Replacement Therapy for Primary Immunodeficiency.原发性免疫缺陷的免疫球蛋白替代疗法
Immunol Allergy Clin North Am. 2015 Nov;35(4):713-30. doi: 10.1016/j.iac.2015.07.006. Epub 2015 Sep 4.
4
Skin Necrosis Following Subcutaneous Immunoglobulin (SCIg).皮下注射免疫球蛋白后的皮肤坏死
J Clin Immunol. 2017 Jan;37(1):27-28. doi: 10.1007/s10875-016-0346-6. Epub 2016 Oct 28.
5
Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.皮下免疫球蛋白治疗通过皮下快速推注与输注泵给药：回顾性分析。
Ann Allergy Asthma Immunol. 2013 Jul;111(1):51-5. doi: 10.1016/j.anai.2013.04.015. Epub 2013 May 22.
6
[Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].[皮下注射免疫球蛋白用于儿童原发性免疫缺陷的替代疗法]
Pol Merkur Lekarski. 2011 Jun;30(180):413-6.
7
A new subcutaneous immune globulin (HyQvia) for primary immunodeficiency.一种用于原发性免疫缺陷的新型皮下注射免疫球蛋白（海曲泊帕）。
Med Lett Drugs Ther. 2015 Aug 31;57(1476):121-2.
8
Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.皮下注射免疫球蛋白IgPro20用于日本原发性免疫缺陷患者的成本最小化分析。
Clin Ther. 2014 Nov 1;36(11):1616-24. doi: 10.1016/j.clinthera.2014.08.007. Epub 2014 Sep 16.
9
[Subcutaneous immunoglobulin substitution and therapy].[皮下免疫球蛋白替代与治疗]
Orv Hetil. 2011 Jan 9;152(2):64-7. doi: 10.1556/OH.2011.28940.
10
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.对于原发性抗体缺陷患者，从静脉注射或16%皮下替代疗法转换为20%皮下免疫球蛋白疗法。
Int J Immunopathol Pharmacol. 2017 Mar;30(1):73-82. doi: 10.1177/0394632016681577. Epub 2016 Dec 7.
引用本文的文献
1
Exploring Multidimensional Risk Factors Associated with Local Adverse Reactions to Subcutaneous Immunoglobulin Therapy: Insights from a Nationwide Multicenter Study.探索与皮下免疫球蛋白治疗局部不良反应相关的多维风险因素：一项全国性多中心研究的见解
Biomedicines. 2025 Aug 15;13(8):1991. doi: 10.3390/biomedicines13081991.
2
Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.新型皮下免疫球蛋白 16.5%（奥坦诺®）治疗原发性免疫缺陷病患者的临床疗效、安全性和耐受性。
Front Immunol. 2019 Feb 4;10:40. doi: 10.3389/fimmu.2019.00040. eCollection 2019.
3
Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".对致编辑的信的回复，信的主题为“在临床试验中评估皮下注射免疫球蛋白（SCIG）的局部不良反应”
J Clin Immunol. 2017 Nov;37(8):739-740. doi: 10.1007/s10875-017-0438-y. Epub 2017 Sep 5.
本文引用的文献
1
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.新型20%皮下注射用人免疫球蛋白的疗效、安全性、耐受性及药代动力学：在欧洲针对原发性免疫缺陷患者开展的2/3期研究
Clin Exp Immunol. 2017 Jan;187(1):146-159. doi: 10.1111/cei.12866. Epub 2016 Oct 18.
2
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.北美原发性免疫缺陷病患者使用新型20%皮下注射用人免疫球蛋白的疗效、安全性及药代动力学
J Clin Immunol. 2016 Oct;36(7):700-12. doi: 10.1007/s10875-016-0327-9. Epub 2016 Aug 31.
3
Association of skin necrosis with subcutaneous immunoglobulin therapy.皮肤坏死与皮下免疫球蛋白治疗的关联。
Ann Allergy Asthma Immunol. 2014 Aug;113(2):232-3. doi: 10.1016/j.anai.2014.05.025. Epub 2014 Jul 2.
4
Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease.欣可来®用于原发性免疫缺陷病治疗的长期疗效、安全性和耐受性。
Clin Immunol. 2014 Feb;150(2):161-9. doi: 10.1016/j.clim.2013.10.008. Epub 2013 Oct 26.
5
Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.静脉或皮下替代治疗剂量等效转换后，Hizentra(®) 在原发性免疫缺陷患者中的疗效和安全性。
Clin Immunol. 2011 Oct;141(1):90-102. doi: 10.1016/j.clim.2011.06.002. Epub 2011 Jun 12.
6
Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.新型 20%皮下免疫球蛋白制剂 IgPro20 治疗原发性免疫缺陷症患者的疗效和安全性。
J Clin Immunol. 2010 Sep;30(5):734-45. doi: 10.1007/s10875-010-9423-4. Epub 2010 May 8.
Zotero 插件